Abstract:Objective To analyze the sero-epidemiological characteristics of hepatitis E virus (HEV) in Shandong province, and thereby to provide evidence for the policy-making of hepatitis E prevention and control. Methods The inhabitants aged between 1-59 years old were randomly selected to participate in the study by two-stage stratified random sampling method from 12 counties in Shandong province in October, 2014. Firstly two townships were selected from each county by probability proportional to size sampling (PPS) method. A total of 5229 participants aged 1-59 years old were selected by stratified random sampling method. All the participants finished a questionnaire survey and a venous blood sample (3-5 ml) was collected from each to test anti-HEV IgG by enzyme-linked assay (ELISA). The weighted prevalence of anti-HEV IgG with different demographic characteristics was estimated. The variance of the positive rate of anti-HEV IgG was calculated by Taylor series linearization method, as well as its 95%CI. A statistical test was conducted to compare the rate of its 95%CI, and the results in the present study were compared with those in sero-survey in 2006. Results A total of 5229 subjects entered the final analysis in 2014. The overall weighed prevalence of anti-HEV IgG was 9.19% (95%CI: 6.18%-12.20%) among natural population in Shandong province, decreased by 19.88% in comparison with that in 2006 sero-survey (11.47%,95%CI: 8.92%-14.02%). The prevalence increased with age increasing(χ2trend=288.11,P<0.001)in 2014, which was similar to the result in 2006 sero-survey. Except for 1-4 years old group, the prevalence of anti-HEV IgG in the other age groups were lower than it in the corresponding groups in 2006. The prevalence of anti-HEV IgG in urban (8.19%, 95%CI:0.00-22.23%), rural areas (9.69%, 95%CI:4.99%-14.38%), eastern areas (12.70%, 95%CI: 0.00-27.72%), central areas (4.74%, 95%CI: 0.00-9.91%) and western areas (9.32%, 95%CI:0.69%-17.94%) in 2014 were all lower than the corresponding prevalences (11.39%, 95%CI: 8.17%-14.62%; 11.92%, 95%CI: 8.75%-15.08%; 22.77%, 95%CI: 14.99%-30.55%; 7.97%, 95%CI: 4.75%-11.20%;10.59%, 95%CI:6.37%-14.82%) in 2006 survey. The prevalence of anti-HEV IgG in coastal areas (16.56%, 95%CI:12.94%-20.18%) and inland areas (7.63%,95%CI:5.16%-10.10%)in 2014 were lower than it in the corresponding areas (28.04%, 95%CI:20.45%-35.64%;9.50%, 95%CI:7.31%-11.70%)in 2006 survey. The prevalence among peasant (11.98%, 95%CI: 8.20%-15.76%), worker (9.68%, 95%CI:4.48%-14.88%), cadre (13.90%, 95%CI: 7.47%-20.33%), service provider (12.26%, 95%CI: 1.80%-22.73%) in 2014 survey were lower than it among the corresponding populations (13.76%, 95%CI:10.15%-17.38%;21.11%, 95%CI:12.67%-29.55%;17.81%, 95%CI:7.63%-28.00%;21.08%, 95%CI:0.03%-42.12%) in 2006 survey. Conclusion The prevalence of anti-HEV IgG has decreased in Shandong province in the recent years, but the epidemiological characteristics found no obvious changes. HEV susceptibility in natural population was generally high. Hepatitis E vaccines were recommended to be used in HEV high-risk population in the province.

Waning of anti-HAV immunity in Shijiazhuang prefecture, Hebei province, China: a comparison of seroprevalence between 1992 and 2011.

Changes in Seroprevalence of Hepatitis A after the Implementation of Universal Childhood Vaccination in Shandong Province, China: A Comparison Between 2006 and 2014.

Changing Epidemiology of Hepatitis A in China: Evidence From Three National Serological Surveys and the National Notifiable Disease Reporting System

Era of Vaccination Heralds a Decline in Incidence of Hepatitis A in High-Risk Groups in China.

A serological and molecular survey of hepatitis B in children 15 years after inception of the national hepatitis B vaccination program in eastern China.

Prevalence of hepatitis A antibody among population covered by different hepatitis A immunization strategies in Shandong Province,2015,China

Epidemiologic trends of hepatitis A in different age groups and regions of China from 1990 to 2018: observational population-based study

A Sero-Epidemiological Study of Hepatitis E among General Population in Shandong Province of China in 2014

Seroprevalence of hepatitis A virus antibody in a population aged 0-30 years in Shanghai, China: implications for hepatitis A immunization.

Protective immune barrier against hepatitis B is needed in individuals born before infant HBV vaccination program in China

Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period.

The Effectiveness of National Expanded Program on Immunization With Hepatitis A Vaccines in the Chinese Mainland: Interrupted Time-Series Analysis

Persistence of Anti-HAV Antibody and Long-Term Protection Conferred by a Single Dose of Live-Attenuated Hepatitis a Vaccine: Results from 17-Year Follow-Up

Comparison between two population-based hepatitis B serosurveys with an 8-year interval in Shandong Province, China.

Epidemiological Serosurvey of Hepatitis B in China--declining HBV Prevalence Due to Hepatitis B Vaccination.

Long-term Persistence of Anti-Hav Antibody Conferred by a Single Dose of Live-Attenuated Hepatitis A Vaccine: Results from 17-Year Follow-Up.

Changing incidence of hepatitis B and persistent infection risk in adults: a population-based follow-up study from 2011 in China

[A Study on Seroprevalence of Anti-Hav IgG in Adults of 4 Cities in China].

Immune Memory at 17-Years of Follow-Up of a Single Dose of Live Attenuated Hepatitis A Vaccine.

Assessing the effectiveness of the expanded hepatitis A vaccination program in China: an interrupted time series design

Seroprevalence of total hepatitis A virus antibody in children and adolescents in Shanghai and its risk factors